Telomir Pharmaceuticals (TELO) Change in Accured Expenses (2023 - 2025)

Telomir Pharmaceuticals has reported Change in Accured Expenses for 3 years, with the latest figure at $207394.0 in Q4 2025.

• Quarterly Change in Accured Expenses rose 155.87% year-over-year to $207394.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$50767.0 (down 127.65% YoY) and the FY2025 annual result came in at -$50767.0, down 127.65% from the prior year.
• Change in Accured Expenses improved to $207394.0 in Q4 2025 per TELO's latest filing, from $74419.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.4 million in Q2 2023 and troughed at -$1.0 million in Q3 2023.
• A 3-year average of $20618.2 and a median of $48584.5 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses jumped 256.29% in 2024, then tumbled 258.23% in 2025.
• Over 3 years, Change in Accured Expenses stood at $22750.0 in 2023, then surged by 256.29% to $81055.0 in 2024, then soared by 155.87% to $207394.0 in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $207394.0, $74419.0, and -$303905.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.